{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:16:31Z","timestamp":1794539791053,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41409-025-02593-3","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:18:40Z","timestamp":1746271120000},"page":"1114-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma"],"prefix":"10.1038","volume":"60","author":[{"given":"Darren","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-5978","authenticated-orcid":false,"given":"Tarek H.","family":"Mouhieddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana C.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Thibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn J.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-4292","authenticated-orcid":false,"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"2593_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2593_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2593_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00527-y","volume":"11","author":"R Bansal","year":"2021","unstructured":"Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J. 2021;11:161.","journal-title":"Blood Cancer J"},{"key":"2593_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45.","journal-title":"Blood Cancer J"},{"key":"2593_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","volume":"54","author":"M Weinstock","year":"2013","unstructured":"Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk lymphoma. 2013;54:1135\u201341.","journal-title":"Leuk lymphoma"},{"key":"2593_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk NW, Anderson KC, Badros A, et al. Expert review on soft\u2010tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194:496\u2013507.","journal-title":"Br J Haematol"},{"key":"2593_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360.","journal-title":"Haematologica"},{"key":"2593_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4110\/in.2017.17.4.250","volume":"17","author":"K Batsukh","year":"2017","unstructured":"Batsukh K, Lee S-E, Min GJ, Park SS, Jeon Y-W, Yoon J-H, et al. Distinct clinical outcomes between paramedullary and extramedullary lesions in newly diagnosed multiple myeloma. Immune Netw. 2017;17:250.","journal-title":"Immune Netw"},{"key":"2593_CR9","first-page":"1514","volume":"109","author":"H Hashmi","year":"2024","unstructured":"Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, et al. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024;109:1514.","journal-title":"Haematologica"},{"key":"2593_CR10","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","DOI":"10.1056\/NEJMoa2303379"},{"key":"2593_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"2593_CR12","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"2593_CR13","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29:2286\u201394.","journal-title":"Nat Med"},{"key":"2593_CR14","doi-asserted-by":"crossref","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17:42.","DOI":"10.1186\/s13045-024-01555-4"},{"key":"2593_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"2593_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w","volume":"14","author":"D Dima","year":"2024","unstructured":"Dima D, Abdallah A-O, Davis JA, Awada H, Goel U, Rashid A, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J. 2024;14:90.","journal-title":"Blood Cancer J"},{"key":"2593_CR17","doi-asserted-by":"crossref","unstructured":"Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat JC, Gonzalez-Calle V, Moreno DF, et al. Clinical impact of [18F] FDG-PET\/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed\/refractory multiple myeloma. Blood Adv. 2025;9:571\u201382 .","DOI":"10.1182\/bloodadvances.2024014360"},{"key":"2593_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.12223","volume":"161","author":"L Billecke","year":"2013","unstructured":"Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161:87\u201394.","journal-title":"Br J Haematol"},{"key":"2593_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ejh.12688","volume":"97","author":"L Besse","year":"2016","unstructured":"Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016;97:93\u2013100.","journal-title":"Eur J Haematol"},{"key":"2593_CR20","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ajh.25579","volume":"94","author":"I Avivi","year":"2019","unstructured":"Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, et al. Hematogenous extramedullary relapse in multiple myeloma\u2010a multicenter retrospective study in 127 patients. Am J Hematol. 2019;94:1132\u201340.","journal-title":"Am J Hematol"},{"key":"2593_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1365-2141.2002.03258.x","volume":"116","author":"IMS Dahl","year":"2002","unstructured":"Dahl IMS, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol. 2002;116:273\u20137.","journal-title":"Br J Haematol"},{"key":"2593_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/path.1680","volume":"205","author":"M Kremer","year":"2005","unstructured":"Kremer M, Ott G, Nathrath M, Specht K, Stecker K, Alexiou C, et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol: A J Pathol Soc Gt Br Irel. 2005;205:92\u2013101.","journal-title":"J Pathol: A J Pathol Soc Gt Br Irel"},{"key":"2593_CR23","doi-asserted-by":"crossref","unstructured":"John M, Helal M, Duell J, Mattavelli G, Stanojkovska E, Afrin N, et al. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood J. 2024;144:2121\u201335.","DOI":"10.1182\/blood.2024024590"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02593-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02593-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02593-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:45:10Z","timestamp":1757162710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02593-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2593"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02593-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DP: Honoraria from Sanofi. THM: Advisory board fees for Sanofi. JR: Consultant\/advisory board: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, Abbvie, Regeneron, Forus, Menarini, Speakers Bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies. SP: Advisory board for Grail; research support from Celgene\/BMS Corporation, Grail, Caribou. SJ: Consulting for Janssen Pharmaceuticals, BMS, Caribou Biosciences, Legend Biotech, Regeneron Pharmaceuticals, Takeda Pharmaceuticals, Sanofi, Poseida Therapeutics; Advisory board for Janssen Pharmaceuticals, BMS, GSK; Data Safety Monitoring Board for Janssen Pharmaceuticals, Sanofi, Genmab. LJS: Consulting\/advisory board for Janssen Pharmaceuticals. CR: Advisory board for Janssen Pharmaceuticals, Takeda Pharmaceuticals, BMS, Amgen, Karyopharm Therapeutics. ACR: Consulting for Johnson & Johnson, Adaptive, BMS, Sanofi. HJC: Employment: The Multiple Myeloma Research Foundation, Research funding: Genentech\/Roche, BMS, Takeda. The remaining authors declare no relevant competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Patient data was retrospectively collected and analyzed in accordance with the Declaration of Helsinki. As many patients were deceased, obtaining informed consent was not possible. Therefore, a waiver of informed consent was granted, and the study was approved by the institutional review board of Mount Sinai (IRB#11-01978-MOD0013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}